Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–116 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AD-MCI Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses

NCT05877196
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Cognitive Impairment, Cognitive Decline, Memory Loss, Memory Impairment
Interventions
Moderate Intensity Continuous Training (MICT), Chair-based Stretch, High-Intensity Interval Training (HIIT), Combined Aerobic Resistance Exercise (CARE)
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
65 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

NCT02423200
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VX-745
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Not applicable Interventional

7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD

NCT05596994
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Lighting Intervention Therapy, Sham LIT
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 25, 2026, 11:24 AM EDT
Recruiting Not applicable Interventional

Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease

NCT05795634
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Trier Social Stress Test
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 25, 2026, 11:24 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)

NCT07180147
View directory record Official record
Conditions
Alzheimer Disease (AD), Cardio Vascular Disease, Mild Cognitive Impairment (MCI), Frailty Syndrome, Disability Physical, Hypertension, Metabolic Syndrome (MetS), Healthy Aging, Obesity &Amp; Overweight
Interventions
Not listed
Lead sponsor
Marymount University
Other
Eligibility
50 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 25, 2026, 11:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Implications for Management of PET Amyloid Classification Technology

NCT02778971
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer's Disease
Interventions
[18F]Flutemetamol
Drug
Lead sponsor
University of Utah
Other
Eligibility
45 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults

NCT01264614
View directory record Official record
Conditions
Cognitive Decline, Dementia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Strengthening exercise
Behavioral
Lead sponsor
Union College, New York
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

NCT02016560
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

NCT00702143
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
15
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 25, 2026, 11:24 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Senicapoc in Alzheimer's Disease

NCT04804241
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Senicapoc, Placebo Tablet
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
55 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Sacramento, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 11:24 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

NCT01931566
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 83 Years
Enrollment
3,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
34
States / cities
Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 25, 2026, 11:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cognitive Detection of Preclinical AD: Validation Using Biomarkers

NCT02616679
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 25, 2026, 11:24 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

FACE Phase II (a Stage II Trial)

NCT07130669
View directory record Official record
Conditions
MCI, Subjective Cognitive Decline (SCD), Mild Behavioral Impairment
Interventions
Cognitive Remediation, Cognitive Remediation II
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
60 Years to 89 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT04602624
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
Interventions
SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Redlands, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

NCT01518374
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
Interventions
Florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Sun City, Arizona • Davis, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 25, 2026, 11:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 2

NCT01231971
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
Interventions
Florbetapir, Flortaucipir
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 25, 2026, 11:24 AM EDT
Recruiting Not applicable Interventional

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

NCT02740634
View directory record Official record
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

NCT04931459
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACU193, Placebo
Drug
Lead sponsor
Acumen Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Scottsdale, Arizona • Anaheim, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 25, 2026, 11:24 AM EDT
Completed No phase listed Observational

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

NCT05364307
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Prescreener database
Other
Lead sponsor
Global Alzheimer's Platform Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
1,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
San Diego, California • Santa Ana, California • Aventura, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 25, 2026, 11:24 AM EDT
Completed Phase 1Phase 2 Interventional

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

NCT04381468
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pepinemab, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 25, 2026, 11:24 AM EDT